Whitelab Genomics raised €23M in a Series B round in Oct 2026. The company is based in Paris, France. Investors in the round: AVP, Blast Club , Debiopharm Innovation Fund and 2 others. Data as of 7 Oct 2026.
Reported in EUR — no conversion. €23M
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
